Report cover image

EMEA Point-Of-Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Cancer Marker, Coagulation Testing, Infectious Disease), By End-use (Clinics, Home), By Region (Europe, MEA), And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Aug 18, 2025
Length 136 Pages
SKU # GV20399992

Description

EMEA point-of-care diagnostics Market Trends

The EMEA point-of-care (POC) diagnostics market size was estimated at USD 14.08 billion in 2024 and is projected to reach USD 23.13 billion by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This market emphasizes rapid diagnostic solutions designed for near-patient testing, enabling timely clinical decisions and improved healthcare outcomes. POC diagnostics in Europe, Middle East, and Africa (EMEA) region span a range of applications, including infectious disease detection, cardiovascular monitoring, blood glucose testing, pregnancy screening, and other critical areas that require swift and reliable results. These solutions are increasingly utilized across hospitals, clinics, and home care settings, reducing the need for centralized laboratory testing.

The market is supported by advancements in portable devices, user-friendly testing kits, and digital connectivity that allow seamless data sharing and integration with healthcare systems. Growing demand for decentralized healthcare, along with efforts to improve diagnostic access in remote areas across Europe, the Middle East, and Africa, is encouraging adoption. Technological innovations, such as microfluidics, lateral flow assays, and molecular diagnostics at the point of care, are reshaping the landscape by enabling faster turnaround times and expanding the range of testable conditions. For instance, in June 2023, Sysmex introduced the first point-of-care antimicrobial susceptibility testing system in Europe. Using proprietary microfluidic technology, this system delivers results in as little as 30 minutes, supporting rapid identification of resistant pathogens and optimizing treatment decisions in clinical settings.

Furthermore, favorable healthcare initiatives and increased awareness of early disease detection are driving investments in POC technologies across the Europe, Middle East, and Africa (EMEA) region. Public and private sector collaborations are strengthening diagnostic networks and accelerating the adoption of cost-effective, rapid testing solutions. The growing focus on digital health integration, supported with telemedicine and connected diagnostic platforms, is expected to further improve patient management and expand the reach of POC diagnostics in both developed and emerging markets within the region.

These innovations are transforming the global high throughput screening landscape by enabling faster, more precise, and cost-effective drug discovery solutions. The integration of AI-driven analytics, microfluidics, and advanced 3D cell models is improving the reliability of screening outcomes and streamlining decision-making. With pharmaceutical and biotechnology companies focusing on efficient lead identification and early-stage validation, these advancements are expected to strengthen drug development pipelines and accelerate time-to-market for novel therapeutics in the coming years.

EMEA Point-of-Care Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the EMEA point-of-care diagnostics market based on product, end-use, and region:
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Glucose Testing
  • Hb1Ac Testing
  • Coagulation Testing
  • Fertility/ Pregnancy
  • Infectious Disease
  • HIV POC
  • Clostridium Difficile POC
  • HBV POC
  • Pneumonia or Streptococcus Associated Infections
  • Respiratory Syncytial Virus (RSV) POC
  • HPV POC
  • Influenza/ Flu POC
  • HCV POC
  • MRSA POC
  • TB and Drug-resistant TB POC
  • HSV POC
  • COVID-19
  • Other Infectious Diseases
  • Cardiac Markers
  • Thyroid Stimulating Hormone
  • Hematology
  • Primary Care Systems
  • Decentralized Clinical Chemistry
  • Feces
  • Lipid Testing
  • Cancer Marker
  • Blood Gas/ Electrolytes
  • Ambulatory Chemistry
  • Drug of Abuse (DOA) Testing
  • Autoimmune Diseases
  • Urinalysis/ Nephrology
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinics
  • Pharmacy & Retail Clinics
  • Physician Office
  • Urgent Care Clinics
  • Hospitals
  • Home
  • Assisted Living Healthcare Facilities
  • Laboratory
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

136 Pages
Chapter 1. EMEA Point-Of-Care Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. EMEA Point-Of-Care Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Product Snapshot
2.3. End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. EMEA Point-Of-Care Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising Burden of Chronic and Infectious Diseases
3.4.2. Shift Toward Decentralized Healthcare
3.4.3. Technological Advancements in POC Devices
3.5. Market Restraint Analysis
3.5.1. Regulatory and Quality Compliance Challenges
3.5.2. Limited Access in Low-Income Regions
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. EMEA Point-Of-Care Diagnostics Market: Product Estimates & Trend Analysis
4.1. EMEA Point-Of-Care Diagnostics Market: Product Movement Analysis
4.2. Glucose Testing
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Hb1Ac Testing
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Coagulation Testing
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Fertility/Pregnancy
4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Infectious Disease
4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. HIV POC
4.6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. Clostridium Difficile POC
4.6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.4. HBV POC
4.6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.5. Pneumonia or Streptococcus Associated Infections
4.6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.6. Respiratory Syncytial Virus (RSV) POC
4.6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.7. HPV POC
4.6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.8. Influenza/Flu POC
4.6.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.9. HCV POC
4.6.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.10. MRSA POC
4.6.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.11. TB and Drug-resistant TB POC
4.6.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.12. HSV POC
4.6.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.13. COVID-19
4.6.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.14. Urinalysis/Nephrology
4.6.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Cardiac Markers
4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Thyroid Stimulating Hormone
4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Hematology
4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.10. Primary Care Systems
4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.11. Decentralized Clinical Chemistry
4.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.12. Feces
4.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.13. Lipid Testing
4.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.14. Cancer Marker
4.14.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.15. Blood Gas/Electrolytes
4.15.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.16. Ambulatory Chemistry
4.16.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.17. Drug of Abuse (DOA) Testing
4.17.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.18. Autoimmune Diseases
4.18.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.19. Urinalysis/Nephrology
4.19.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. EMEA Point-Of-Care Diagnostics Market: End Use Estimates & Trend Analysis
5.1. EMEA Point-Of-Care Diagnostics Market: End Use Movement Analysis
5.2. Clinics
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.2.2. Pharmacy & Retail Clinics
5.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.2.3. Physician Office
5.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.2.4. Urgent Care Clinics
5.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Hospitals
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Home
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Assisted Living Healthcare Facilities
5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Laboratory
5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. EMEA Point-Of-Care Diagnostics Market: Regional Business Analysis
6.1. Regional Market Snapshot
6.2. Europe
6.2.1. Europe EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.2. UK
6.2.2.1. UK EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.2.2. Key Country Dynamics
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Scenario
6.2.2.5. Competitive Scenario
6.2.3. Germany
6.2.3.1. Germany EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.3.2. Key Country Dynamics
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Scenario
6.2.3.5. Competitive Scenario
6.2.4. Spain
6.2.4.1. Spain EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.4.2. Key Country Dynamics
6.2.4.3. Regulatory Framework
6.2.4.4. Reimbursement Scenario
6.2.4.5. Competitive Scenario
6.2.5. France
6.2.5.1. France EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.5.2. Key Country Dynamics
6.2.5.3. Regulatory Framework
6.2.5.4. Reimbursement Scenario
6.2.5.5. Competitive Scenario
6.2.6. Italy
6.2.6.1. Italy EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.6.2. Key Country Dynamics
6.2.6.3. Regulatory Framework
6.2.6.4. Reimbursement Scenario
6.2.6.5. Competitive Scenario
6.2.7. Denmark
6.2.7.1. Denmark EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.7.2. Key Country Dynamics
6.2.7.3. Regulatory Framework
6.2.7.4. Reimbursement Scenario
6.2.7.5. Competitive Scenario
6.2.8. Sweden
6.2.8.1. Sweden EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.8.2. Key Country Dynamics
6.2.8.3. Regulatory Framework
6.2.8.4. Reimbursement Scenario
6.2.8.5. Competitive Scenario
6.2.9. Norway
6.2.9.1. Norway EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.2.9.2. Key Country Dynamics
6.2.9.3. Regulatory Framework
6.2.9.4. Reimbursement Scenario
6.2.9.5. Competitive Scenario
6.3. MEA
6.3.1. MEA EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.3.2. South Africa
6.3.2.1. South Africa EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.3.2.2. Key Country Dynamics
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Scenario
6.3.2.5. Competitive Scenario
6.3.3. Saudi Arabia
6.3.3.1. Saudi Arabia EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.3.3.2. Key Country Dynamics
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Scenario
6.3.3.5. Competitive Scenario
6.3.4. UAE
6.3.4.1. UAE EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.3.4.2. Key Country Dynamics
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Scenario
6.3.4.5. Competitive Scenario
6.3.5. Kuwait
6.3.5.1. Kuwait EMEA Point-Of-Care Diagnostics Market, 2021 - 2033 (USD Million)
6.3.5.2. Key Country Dynamics
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Scenario
6.3.5.5. Competitive Scenario
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.2.1. New Biomarker Launch
7.2.2. Partnerships
7.2.3. Acquisition
7.2.4. Collaboration
7.2.5. Funding
7.3. Key Company Market Share Analysis, 2024
7.4. Company Heat Map Analysis
7.5. Company Profiles
7.5.1. F. Hoffmann-La Roche Ltd
7.5.1.1. Company Overview
7.5.1.2. Financial Performance
7.5.1.3. Biomarker Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. QIAGEN
7.5.2.2. Financial Performance
7.5.2.3. Biomarker Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Danaher Corporation
7.5.3.1. Company Overview
7.5.3.2. Financial Performance
7.5.3.3. Biomarker Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. BD
7.5.4.1. Company Overview
7.5.4.2. Financial Performance
7.5.4.3. Biomarker Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. bioMérieux
7.5.5.1. Company Overview
7.5.5.2. Financial Performance
7.5.5.3. Biomarker Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Abbott
7.5.6.1. Company Overview
7.5.6.2. Financial Performance
7.5.6.3. Biomarker Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Siemens Healthcare Private Limited
7.5.7.1. Company Overview
7.5.7.2. Financial Performance
7.5.7.3. Biomarker Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Werfen
7.5.8.1. Company Overview
7.5.8.2. Financial Performance
7.5.8.3. Biomarker Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Nova Biomedical
7.5.9.1. Company Overview
7.5.9.2. Financial Performance
7.5.9.3. Biomarker Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Trividia Health, Inc.
7.5.10.1. Company Overview
7.5.10.2. Financial Performance
7.5.10.3. Biomarker Benchmarking
7.5.10.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us